• 1. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 2. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 5. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707

Recent Advances in the Study of 3,5-Dichloro-4-fluoro-2-iodoaniline (CAS: 1699384-74-1) in Chemical Biology and Pharmaceutical Research

3,5-Dichloro-4-fluoro-2-iodoaniline (CAS: 1699384-74-1) is a halogenated aniline derivative that has recently gained attention in chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery. This compound, characterized by its multiple halogen substitutions, serves as a versatile intermediate in the synthesis of complex molecules, particularly in the development of novel therapeutic agents. Recent studies have explored its utility in medicinal chemistry, focusing on its role as a building block for targeted drug design and its potential biological activities.

One of the key areas of interest is the use of 3,5-Dichloro-4-fluoro-2-iodoaniline in the synthesis of kinase inhibitors. Kinases are critical targets in cancer therapy, and the halogen-rich structure of this compound allows for precise modifications to enhance binding affinity and selectivity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its incorporation into a series of tyrosine kinase inhibitors, showing promising results in preclinical models of non-small cell lung cancer. The study highlighted the compound's ability to improve pharmacokinetic properties, such as metabolic stability and solubility, compared to non-halogenated analogs.

In addition to its applications in oncology, recent research has investigated the antimicrobial potential of derivatives of 3,5-Dichloro-4-fluoro-2-iodoaniline. A team at the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters that halogenated anilines, including this compound, exhibit significant activity against drug-resistant bacterial strains. The study attributed this activity to the electron-withdrawing effects of the halogens, which enhance the compound's interaction with bacterial enzymes involved in cell wall synthesis. These findings open new avenues for developing antibiotics to combat multidrug-resistant infections.

Another notable development is the use of 3,5-Dichloro-4-fluoro-2-iodoaniline in radiopharmaceuticals. The iodine atom in its structure makes it a candidate for radiolabeling, enabling its use in positron emission tomography (PET) imaging. A 2024 study in Nuclear Medicine and Biology explored its incorporation into radiotracers for detecting tumor hypoxia. The researchers found that the compound's stability under physiological conditions and its ability to accumulate in hypoxic tissues make it a promising tool for diagnostic imaging.

Despite these advancements, challenges remain in optimizing the synthesis and scalability of 3,5-Dichloro-4-fluoro-2-iodoaniline. Recent work published in Organic Process Research & Development addressed these issues by developing a more efficient and environmentally friendly synthetic route. The new method reduces the use of hazardous reagents and improves yield, making the compound more accessible for large-scale pharmaceutical applications.

In conclusion, 3,5-Dichloro-4-fluoro-2-iodoaniline (CAS: 1699384-74-1) represents a valuable scaffold in modern drug discovery, with applications ranging from kinase inhibitors to antimicrobial agents and radiopharmaceuticals. Ongoing research continues to uncover its potential, driven by its unique chemical properties and versatility. Future studies are expected to focus on further optimizing its derivatives for clinical use and expanding its applications in other therapeutic areas.

• 852569-38-1(5-chloro-4-fluoro-2-iodoaniline)
• 1268684-06-5(3-chloro-2-fluoro-6-iodoaniline)
• 1935087-03-8(Benzenamine, 5-chloro-2-fluoro-4-iodo-)
• 874840-61-6(3-Chloro-2-fluoro-4-iodoaniline)
• 1094759-93-9(4-Chloro-5-fluoro-2-iodoaniline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)